Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
Sandoz launches biosimilar Pyzchiva® (ustekinumab-ttwe) in the US, offering new treatment for around 12 million patients[1-4]
Seeking Alpha / 1 hour from now 1 Views
Seeking Alpha / 1 hour from now 1 Views
Ad hoc announcement pursuant to art. 53 SIX Swiss Exchange Listing Rules
Comments